Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Publication year range
1.
Clin Chem Lab Med ; 37(7): 735-8, 1999 Jul.
Article in English | MEDLINE | ID: mdl-10510731

ABSTRACT

Clinical laboratory procedures using cerebrospinal fluid (CSF) to assist in the diagnosis of multiple sclerosis (MS) are based essentially on the determination of oligoclonal bands (OB) in CSF and not in serum. To date, the techniques using isoelectric focusing (IEF) have represented one of the most efficient methods for detecting supernumerary bands in CSF but unfortunately were not always compatible with a routine use. Here, we describe a revised method of IEF suitable for the diagnosis of neurological disorders. The kit-based technique was simplified and the present procedure allowed an easier execution, reduced the overall analysis time and permitted an uncomplicated intepretation of oligoclonal profiles. Moreover, the technique developed was very sensitive and specific for the diagnosis of MS diagnosis. In conclusion, the IEF protocol described in this report is suitable for OB detection in any laboratory.


Subject(s)
Immunoglobulin G/cerebrospinal fluid , Isoelectric Focusing/methods , Multiple Sclerosis/diagnosis , Central Nervous System Diseases/diagnosis , Humans , Immunoglobulin G/blood , Multiple Sclerosis/cerebrospinal fluid , Predictive Value of Tests , Sensitivity and Specificity
2.
Leukemia ; 13(4): 641-4, 1999 Apr.
Article in English | MEDLINE | ID: mdl-10214874

ABSTRACT

As in other hematological malignancies, the achievement of a complete remission (CR) is important in multiple myeloma but is still based on common cytological and electrophoretic criteria. In this report, we studied 14 patients who achieved an apparent CR following high-dose therapy using fluorescence in situ hybridization (FISH) analysis. Although the results were difficult to interpret in two patients, 12 of 14 patients had unequivocal persistence of abnormal plasma cells in their bone marrow. Our results suggest that only a few patients, if any, are in true CR following one course of high-dose therapy and are in favor of post-transplantation treatments.


Subject(s)
In Situ Hybridization, Fluorescence , Multiple Myeloma/pathology , Adult , Aged , Antineoplastic Agents, Alkylating/administration & dosage , Antineoplastic Agents, Alkylating/therapeutic use , Bone Marrow/pathology , Chromosome Aberrations , Female , Hematopoietic Stem Cell Transplantation , Humans , Interphase , Male , Melphalan/administration & dosage , Melphalan/therapeutic use , Middle Aged , Multiple Myeloma/drug therapy , Multiple Myeloma/mortality , Multiple Myeloma/therapy , Myeloma Proteins/analysis , Neoplasm Recurrence, Local , Neoplasm, Residual , Neoplastic Stem Cells/pathology , Plasma Cells/pathology , Remission Induction , Survival Analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...